OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLC

Chicago Capital LLC lowered its stake in shares of OmniAb, Inc. (NASDAQ:OABI) by 0.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,182,970 shares of the company’s stock after selling 4,382 shares during the period. Chicago Capital LLC owned 2.71% of OmniAb worth $11,936,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in OABI. ADAR1 Capital Management LLC purchased a new position in OmniAb during the fourth quarter worth about $2,950,000. Isthmus Partners LLC lifted its position in OmniAb by 18.3% during the fourth quarter. Isthmus Partners LLC now owns 310,774 shares of the company’s stock worth $1,917,000 after buying an additional 48,138 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in OmniAb by 56.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,772 shares of the company’s stock worth $116,000 after buying an additional 6,755 shares during the period. Simplicity Wealth LLC raised its holdings in shares of OmniAb by 23.3% in the 2nd quarter. Simplicity Wealth LLC now owns 42,160 shares of the company’s stock worth $158,000 after purchasing an additional 7,976 shares during the period. Finally, Jump Financial LLC raised its holdings in shares of OmniAb by 157.1% in the 4th quarter. Jump Financial LLC now owns 49,732 shares of the company’s stock worth $307,000 after purchasing an additional 30,386 shares during the period. Institutional investors and hedge funds own 72.08% of the company’s stock.

OmniAb Stock Performance

Shares of NASDAQ:OABI traded down $0.14 during mid-day trading on Friday, hitting $3.97. 549,874 shares of the company traded hands, compared to its average volume of 538,428. The firm has a market cap of $466.93 million, a P/E ratio of -6.20 and a beta of -0.13. OmniAb, Inc. has a 52-week low of $3.56 and a 52-week high of $6.72. The firm’s 50 day simple moving average is $4.29 and its 200 day simple moving average is $4.65.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. OmniAb had a negative return on equity of 20.21% and a negative net margin of 287.29%. The firm had revenue of $7.61 million during the quarter, compared to analyst estimates of $6.52 million. During the same quarter last year, the firm earned ($0.15) EPS. Equities research analysts expect that OmniAb, Inc. will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a report on Monday, August 12th. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price objective on shares of OmniAb in a report on Friday, August 16th. Finally, Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a report on Monday, August 19th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.